Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The Stanford Health Care Center for Memory Disorders is encouraged that there is a new treatment option for certain patients with Alzheimer’s disease. On January 6, 2023, the FDA granted accelerated approval for lecanemab (LeqembiTM).
Because the cause of the disease is unknown, there are no prevention protocols to follow at this time. And, because the controllable risk factors for Alzheimer's disease are not clear, it is not yet possible to reduce the chances of developing the disease. Exercise, social interaction and intellectual stimulation can help slow cognitive decline.
Open trials refer to studies currently recruiting participants or that may recruit participants in the near future. Closed trials are not currently enrolling, but similar studies may open in the future.
Closed trials are not currently enrolling, but may open in the future.